Annex II Essential medical uses

Quota of controlled substances of Group I that may be used in the production of metered dose inhalers (MDIs) for the treatment of asthma and other chronic obstructive pulmonary diseases (COPDs) are allocated to:

• 3 M Health Care Ltd (UK)

• Bespak Europe Ltd (UK)

• Boehringer Ingelheim GmbH (DE)

• Chiesi Farmaceutici SpA (IT)

• Inyx Pharmaceuticals Ltd (UK)

• Ivax Ltd (IE)

• Laboratorio Aldo Union SA (ES)

• SICOR SpA (IT)

• Valeas SpA Pharmaceuticals (IT)

• Valvole Aerosol Research Italiana (VARI)

  SpA — LINDAL Group Italia (IT)